Roche has revealed new results from a phase 2 trial of its oral BTK inhibitor fenebrutinib in relapsing multiple sclerosis (MS) that suggest it can prevent progression of the disease for nearly two ...
To stay on top of changing weather conditions be sure to download our free WSOC-TV Weather app.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results